Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PCVX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVaxcyte appoints vaccine industry veteran Moncef Slaoui to board
Filed June 23, 2026 · Period ending June 17, 2026 · ~1 min read
Key Changes
-
medium
Moncef Slaoui appointed as Class II director effective June 17, 2026, with term expiring at 2028 annual meeting. Board determined he qualifies as independent under Nasdaq rules.
Item 5.02 verify on EDGAR → -
low
Jacks Lee retired from the Board effective June 17, 2026. Retirement was not due to any disagreement with the Company; Lee entered consulting agreement to advise on global supply and manufacturing.
Item 5.02 verify on EDGAR → -
low
Slaoui will receive standard non-employee director compensation with annual equity grant value of $430,000, consistent with the Company's director compensation program.
Item 5.02 verify on EDGAR →
Summary
Vaxcyte executed a planned board transition, with director Jacks Lee retiring and being immediately replaced by Moncef Slaoui as a Class II director on June 17, 2026. The filing explicitly confirms Lee's departure was amicable, with no disagreements or disputes, and he will continue advising the company on manufacturing and supply chain matters under a consulting arrangement. The appointment of Dr.
Slaoui represents a standard board refresh for a clinical-stage vaccine company. He qualifies as independent under Nasdaq listing standards and will serve until the 2028 annual meeting. His compensation follows the company's existing director program, with a $430,000 annual equity grant. This is a routine governance matter with no material operational or strategic implications for shareholders.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Dr. Slaoui will receive compensation in accordance with the Company’s non-employee director compensation program as in effect from time to time (the “Director Compensation Program”), as most recently described under the section titled “Non-Employee Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 23, 2026; provided, however, that the equivalent value of the annual equity grant for all directors is currently set at $430,000.
Dr. Slaoui will receive standard non-employee director compensation as described in the April 2026 proxy statement, with the annual equity grant value currently set at $430,000. The Company also entered into its standard indemnification agreement with him.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 23, 2026 · How we verify